K Pajtler
K Pajtler
Unknown affiliation
Verified email at dkfz.de
TitleCited byYear
Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups
KW Pajtler, H Witt, M Sill, DTW Jones, V Hovestadt, F Kratochwil, K Wani, ...
Cancer cell 27 (5), 728-743, 2015
4542015
DNA methylation-based classification of central nervous system tumours
D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ...
Nature 555 (7697), 469-474, 2018
3932018
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy
JH Schulte, S Lim, A Schramm, N Friedrichs, J Koster, R Versteeg, I Ora, ...
Cancer research 69 (5), 2065-2071, 2009
3902009
New brain tumor entities emerge from molecular classification of CNS-PNETs
D Sturm, BA Orr, UH Toprak, V Hovestadt, DTW Jones, D Capper, M Sill, ...
Cell 164 (5), 1060-1072, 2016
3302016
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
2362018
Cancer screening recommendations for individuals with Li-Fraumeni syndrome
CP Kratz, MI Achatz, L Brugieres, T Frebourg, JE Garber, MLC Greer, ...
Clinical Cancer Research 23 (11), e38-e45, 2017
1242017
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
A Sprüssel, JH Schulte, S Weber, M Necke, K Händschke, T Thor, ...
Leukemia 26 (9), 2039-2051, 2012
1222012
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants
KW Pajtler, SC Mack, V Ramaswamy, CA Smith, H Witt, A Smith, ...
Acta neuropathologica 133 (1), 5-12, 2017
1212017
Accurate prediction of neuroblastoma outcome based on miRNA expression profiles
JH Schulte, B Schowe, P Mestdagh, L Kaderali, P Kalaghatgi, S Schlierf, ...
International journal of cancer 127 (10), 2374-2385, 2010
982010
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma
JH Schulte, HS Bachmann, B Brockmeyer, K DePreter, A Oberthür, ...
Clinical Cancer Research 17 (15), 5082-5092, 2011
962011
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis
V Ramaswamy, T Hielscher, SC Mack, A Lassaletta, T Lin, KW Pajtler, ...
Journal of clinical oncology 34 (21), 2468, 2016
822016
Childhood cancer predisposition syndromes—a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology
T Ripperger, SS Bielack, A Borkhardt, IB Brecht, B Burkhardt, ...
American journal of medical genetics Part A 173 (4), 1017-1037, 2017
692017
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
SM Waszak, PA Northcott, I Buchhalter, GW Robinson, C Sutter, ...
The Lancet Oncology 19 (6), 785-798, 2018
652018
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling
SC Mack, KW Pajtler, L Chavez, K Okonechnikov, KC Bertrand, X Wang, ...
Nature 553 (7686), 101-105, 2018
582018
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
A Künkele, K De Preter, L Heukamp, T Thor, KW Pajtler, W Hartmann, ...
Neuro-oncology 14 (7), 859-869, 2012
522012
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
KW Pajtler, J Wen, M Sill, T Lin, W Orisme, B Tang, JM Hübner, ...
Acta neuropathologica 136 (2), 211-226, 2018
392018
Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk
A Villani, MLC Greer, JM Kalish, A Nakagawara, KL Nathanson, ...
Clinical Cancer Research 23 (12), e83-e90, 2017
392017
Telomere dysfunction and chromothripsis
A Ernst, DTW Jones, KK Maass, A Rode, KI Deeg, BMC Jebaraj, ...
International journal of cancer 138 (12), 2905-2914, 2016
292016
Molecular mechanisms and therapeutic targets in pediatric brain tumors
KW Liu, KW Pajtler, BC Worst, SM Pfister, RJ Wechsler-Reya
Science signaling 10 (470), 2017
262017
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma
KW Pajtler, C Weingarten, T Thor, A Künkele, LC Heukamp, R Büttner, ...
Acta neuropathologica communications 1 (1), 19, 2013
262013
The system can't perform the operation now. Try again later.
Articles 1–20